Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROBIN: Brolucizumab in nAMD
NCT04287348Phase 4Terminated
- Sponsor
- Vista Klinik
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Vista Klinik. Started Jul 2020; status: terminated.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04287348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287348.